Export your learner materials as an interactive game, a webpage, or FAQ style cheatsheet.
Unsaved Work Found!
It looks like you have unsaved work from a previous session. Would you like to restore it?
Total Categories: 7
Does Cannabidiol (CBD) amplify the psychoactive effects of THC?
Answer: False
No, CBD is known to attenuate, or reduce, the psychoactive properties of THC, influencing the overall effect profile of cannabis preparations.
Are *Cannabis indica* and *Cannabis sativa* the two main species known for producing psychoactive cannabinoids?
Answer: True
Yes, *Cannabis indica* and *Cannabis sativa* are the two primary species within the genus *Cannabis* recognized for producing significant amounts of psychoactive cannabinoids.
Does cannabis contain over 460 compounds, with approximately 80 of them being cannabinoids?
Answer: True
Yes, cannabis contains over 460 identified compounds, of which at least 80 are classified as cannabinoids.
Are CB1 cannabinoid receptors primarily located in peripheral tissues, modulating inflammation?
Answer: False
No, CB1 receptors are predominantly found in the brain and are linked to psychoactive effects, while CB2 receptors are located more peripherally and are thought to modulate pain and inflammation.
Is the species *Cannabis ruderalis* known for producing high levels of psychoactive cannabinoids?
Answer: False
No, *Cannabis ruderalis* is known for having minimal psychogenic properties, unlike *Cannabis indica* and *Cannabis sativa*.
Is Tetrahydrocannabinol (THC) the primary cannabinoid responsible for the psychoactive effects of cannabis?
Answer: True
Yes, THC is the principal psychoactive cannabinoid in cannabis, responsible for the characteristic 'high'.
Does the endocannabinoid system involve receptors that interact with compounds from the cannabis plant?
Answer: True
Yes, the endocannabinoid system comprises receptors that interact with both the body's own endocannabinoids and plant-derived phytocannabinoids like THC and CBD.
Are CB1 receptors primarily associated with modulating pain and inflammation?
Answer: False
No, CB1 receptors are primarily associated with psychoactive effects in the brain, while CB2 receptors are more involved in modulating pain and inflammation in peripheral tissues.
Is THC the primary psychoactive cannabinoid, while CBD is non-psychoactive and can reduce THC's effects?
Answer: True
Yes, THC is the main psychoactive compound, whereas CBD is non-psychoactive and known to modulate or reduce THC's psychoactive properties, possessing its own therapeutic potential.
Is the primary function of CB2 receptors to mediate the psychoactive effects of THC?
Answer: False
No, the primary function of CB2 receptors is associated with modulating pain and inflammation in peripheral tissues, whereas CB1 receptors mediate psychoactive effects.
How does CBD influence the effects of THC, according to a 2014 review?
Answer: CBD attenuates (reduces) the psychoactive properties of THC.
A 2014 review indicated that CBD is known to attenuate, or reduce, the psychoactive properties of THC, influencing the overall effect profile of cannabis preparations.
Which two primary species of the *Cannabis* genus are noted for producing psychoactive cannabinoids?
Answer: *Cannabis indica* and *Cannabis sativa*
The primary species of the *Cannabis* genus known for producing significant amounts of psychoactive cannabinoids are *Cannabis indica* and *Cannabis sativa*.
Approximately how many compounds are found in cannabis, and how many of these are cannabinoids?
Answer: Over 460 compounds, about 80 cannabinoids.
Cannabis contains over 460 identified compounds, with at least 80 of these classified as cannabinoids. These compounds interact with the body's cannabinoid receptors.
Where are CB1 cannabinoid receptors predominantly found, and what physiological effects are they primarily linked to?
Answer: The brain; psychoactive effects.
CB1 receptors are predominantly located in the central nervous system and are associated with psychoactive effects, while CB2 receptors are found more in peripheral tissues and are linked to immune function and inflammation modulation.
What is the primary psychoactive compound in cannabis?
Answer: Delta-9-tetrahydrocannabinol (THC)
THC (delta-9-tetrahydrocannabinol) is the primary psychoactive cannabinoid responsible for the 'high' associated with cannabis.
What is the role of the endocannabinoid system in relation to cannabis compounds?
Answer: It involves receptors that interact with both the body's own endocannabinoids and plant-derived phytocannabinoids.
The endocannabinoid system is a crucial biological system that includes endocannabinoids produced by the body and cannabinoid receptors (CB1 and CB2). Phytocannabinoids from the cannabis plant, such as THC and CBD, interact with these same receptors, influencing various physiological processes.
Which of the following is the primary psychoactive cannabinoid in cannabis?
Answer: Delta-9-tetrahydrocannabinol (THC)
THC (delta-9-tetrahydrocannabinol) is the primary psychoactive cannabinoid responsible for the 'high' associated with cannabis.
What is the main difference in location and function between CB1 and CB2 receptors?
Answer: CB1 is in the brain (psychoactivity), CB2 is in the periphery (pain/inflammation).
CB1 receptors are primarily located in the brain and are associated with psychoactive effects. CB2 receptors are predominantly found in peripheral tissues and are linked to modulating pain and inflammation.
Does oral administration of THC result in higher bioavailability and faster absorption compared to inhalation?
Answer: False
No, inhalation or vaporization of THC generally results in higher bioavailability and faster absorption compared to oral administration.
Does the metabolism of THC via edible consumption lead to a less potent psychoactive effect compared to inhalation?
Answer: False
No, the liver metabolism of THC into 11-OH-THC from edibles often results in heightened and prolonged psychoactive effects compared to inhalation.
Are THC and CBD metabolites primarily excreted through urine?
Answer: False
No, THC and CBD metabolites are primarily excreted via feces, with a smaller proportion excreted in urine.
Is the terminal half-life of THC significantly shorter than that of CBD?
Answer: False
No, the terminal half-life of THC (25-36 hours) is comparable to, and potentially longer than, that of CBD (18-32 hours), indicating prolonged presence in the body.
Which route of administration generally offers higher bioavailability for THC compared to oral intake?
Answer: Inhalation or vaporization
Inhaled or vaporized THC exhibits higher bioavailability (10-35%) and faster onset compared to oral administration, which is more variable and has a delayed peak plasma concentration.
How does the metabolism of THC in edibles contribute to their effects?
Answer: It involves liver metabolism into 11-OH-THC, contributing to heightened psychoactive effects.
When consumed as edibles, THC undergoes first-pass metabolism in the liver into 11-OH-THC, which contributes to more potent and prolonged psychoactive effects compared to other routes of administration.
Where are THC and CBD metabolites primarily excreted from the body?
Answer: Primarily through feces.
Due to extensive metabolism, THC and CBD metabolites are primarily excreted via feces, with a smaller portion eliminated through urine. Approximately 65% of THC and a similar proportion of CBD are excreted in feces.
What is the approximate terminal half-life range for THC in the body?
Answer: 25-36 hours
The terminal half-life of THC is estimated to range between 25 to 36 hours, indicating that this compound can persist in the body for a considerable period.
Did William Brooke O'Shaughnessy discover cannabis's analgesic and anticonvulsant effects in Europe?
Answer: False
No, William Brooke O'Shaughnessy introduced cannabis to Western medicine after discovering its analgesic and anticonvulsant effects in India in the 1830s, bringing it back to Europe.
Did the medical use of cannabis decline due to its ease of administration and solubility?
Answer: False
No, the medical use of cannabis declined due to difficulties in dosage control and the rise of more easily administered drugs, not due to ease of administration or solubility.
Did the Marihuana Tax Act of 1937 lead to a resurgence in the medical use of cannabis in the US?
Answer: False
No, the Marihuana Tax Act of 1937 imposed strict regulations and taxes, contributing to the decline of medical cannabis use, not a resurgence.
Do ancient Egyptian texts, such as the Ebers Papyrus, describe the use of cannabis for pain relief?
Answer: True
Yes, the Ebers Papyrus, an ancient Egyptian medical text, describes the use of cannabis for various ailments, including pain relief.
Did ancient Greek physicians use cannabis primarily to treat insomnia?
Answer: False
Ancient Greek physicians used cannabis for various purposes, including treating horses' wounds and expelling tapeworms in humans, but its primary use for insomnia is more strongly associated with ancient Indian texts.
Does the Ebers Papyrus, an ancient Egyptian document, mention the use of cannabis?
Answer: True
Yes, the Ebers Papyrus, dating to approximately 1550 BCE, is one of the earliest known documents describing the medical use of cannabis.
Did medieval Arabic physicians not utilize cannabis in their medical practices?
Answer: False
No, medieval Arabic physicians extensively utilized *Cannabis sativa*, recognizing and documenting its diuretic, antiemetic, analgesic, and anti-inflammatory properties.
Did the rise of the hypodermic syringe contribute to the decline of cannabis use in the late 19th century?
Answer: True
Yes, the advent of the hypodermic syringe favored injectable drugs over cannabis, which is not water-soluble, contributing to its decline in medical use.
Who is credited with introducing cannabis to Western medicine, and where did they conduct their initial observations?
Answer: William Brooke O'Shaughnessy; India
William Brooke O'Shaughnessy, an Irish physician, is credited with introducing cannabis to Western medicine. His research in India during the 1830s identified its analgesic and anticonvulsant properties, leading to its introduction in Europe and the United States.
What factors contributed to the decline of cannabis's medical use by the end of the 19th century?
Answer: Difficulties in dosage control and the rise of easily administered drugs like opium derivatives.
The medical use of cannabis declined due to challenges in dosage control and the emergence of more easily administered drugs, such as opium derivatives. The development of the hypodermic syringe also favored injectable medications over cannabis, which is not water-soluble.
What was the impact of the Marihuana Tax Act of 1937 on medical cannabis in the US?
Answer: It removed cannabis from the U.S. Pharmacopeia and imposed strict regulations, contributing to its decline.
The Marihuana Tax Act of 1937 imposed significant regulations and taxes on cannabis, contributing to its removal from the U.S. Pharmacopeia and a substantial decline in its medical use.
What historical Egyptian medical text describes the use of cannabis?
Answer: The Ebers Papyrus
The Ebers Papyrus, an ancient Egyptian medical text from approximately 1550 BCE, is significant for being one of the earliest known documents describing the medical use of cannabis, including prescriptions for inflammation and pain.
Which of the following is NOT mentioned as a historical use of cannabis in ancient India or Greece?
Answer: Relieving hemorrhoid pain (Egypt)
Ancient Greek physicians used cannabis for horses' wounds and expelling tapeworms. Ancient Indian texts mention its use for insomnia and headaches. Relieving hemorrhoid pain is mentioned in ancient Egyptian texts (Ebers Papyrus), not specifically India or Greece in the provided context.
What role did Arabic physicians play regarding cannabis during the medieval Islamic Golden Age?
Answer: They extensively utilized *Cannabis sativa*, recognizing various medicinal properties.
During the medieval Islamic Golden Age (8th-18th centuries), Arabic physicians extensively utilized *Cannabis sativa*, recognizing and documenting its diuretic, antiemetic, analgesic, and anti-inflammatory properties, integrating it into their medical practices.
Which historical event significantly reduced the medical use of cannabis in the US by imposing regulations and taxes?
Answer: The Marihuana Tax Act of 1937
The Marihuana Tax Act of 1937 imposed significant regulations and taxes on cannabis, contributing to its removal from the U.S. Pharmacopeia and a substantial decline in its medical use.
Is the evidence supporting the benefits of cannabis-based medicines considered conclusive and robust?
Answer: False
Systematic reviews indicate that the evidence for the benefits of cannabis-based medicines is generally of low-to-moderate quality and often inconclusive, with frequent mild adverse effects reported.
Does research suggest that cannabis-based medicines are highly effective for treating chronic pain, supported by strong evidence?
Answer: False
No, research indicates that while low-quality evidence suggests modest relief for chronic pain, the evidence is limited and inconsistent, and harms may outweigh benefits.
Did analysis of the NHANES data reveal significant differences in sleep duration between cannabis users and non-users?
Answer: False
No, analysis of NHANES data did not find significant differences in sleep duration between cannabis users and non-users.
Is medical cannabis considered a primary treatment option for chemotherapy-induced nausea and vomiting (CINV)?
Answer: False
Medical cannabis may be considered an option for patients who do not improve with standard antiemetic treatments, but it is not typically considered a primary treatment option.
Did a Cochrane review find cannabinoids to be highly effective for chemotherapy-induced nausea in children, with minimal side effects?
Answer: False
A Cochrane review suggested cannabinoids were probably effective for chemotherapy-induced nausea in children, but noted a high side-effect profile, primarily drowsiness and dizziness.
Is the efficacy of cannabis for neurological conditions like Multiple Sclerosis (MS) well-established with extensive research?
Answer: False
No, the efficacy of cannabis for neurological conditions like MS is not clearly established and requires more research, although some evidence suggests potential benefits for spasticity.
Is cannabis use consistently linked to anxiety relief, with strong evidence supporting this effect?
Answer: False
While some users report anxiety relief, the overall evidence is inconclusive, and the relationship between cannabis use and anxiety is complex.
What is the general finding regarding the quality of evidence for the benefits of cannabis-based medicines?
Answer: The evidence is generally of low-to-moderate quality and often inconclusive.
Systematic reviews indicate that the evidence for the benefits of cannabis-based medicines is generally of low-to-moderate quality and often inconclusive, with frequent mild adverse effects reported.
What is the evidence regarding the effectiveness of cannabis-based medicines for chronic pain?
Answer: Low-quality evidence suggests modest relief, but harms may outweigh benefits.
Low-quality evidence suggests that cannabis-based medicines may offer modest relief for chronic pain, particularly neuropathic pain, and may provide slight improvements in function and sleep. However, the evidence is limited and inconsistent, and potential harms might outweigh benefits.
What did research on the National Health and Nutrition Examination Survey (NHANES) find about cannabis use and sleep duration?
Answer: There were no significant differences in sleep duration between users and non-users.
Analysis of National Health and Nutrition Examination Survey (NHANES) data did not reveal significant differences in sleep duration between cannabis users and non-users, suggesting no substantial alteration in overall sleep patterns across the population.
According to a Cochrane review, what was a significant concern regarding the use of cannabinoids for chemotherapy-induced nausea in children?
Answer: High side-effect profile, including drowsiness and dizziness
A 2016 Cochrane review indicated that cannabinoids were likely effective for chemotherapy-induced nausea in children. However, a significant concern was the high side-effect profile, primarily drowsiness and dizziness, along with altered moods and increased appetite.
What is the status of cannabis efficacy for neurological conditions like Multiple Sclerosis (MS) according to the text?
Answer: Not clearly established, requiring more research.
The efficacy of cannabis for neurological conditions, including Multiple Sclerosis (MS), is not definitively established and requires further research. While some evidence suggests oral cannabis extract may reduce spasticity, its widespread approval is limited.
Are dizziness and fatigue commonly reported short-term side effects of medical cannabis?
Answer: True
Yes, short-term use of medical cannabis can lead to common adverse effects such as dizziness and feeling tired, which may impair abilities like driving until tolerance develops.
Do potential long-term concerns of medical cannabis use include memory enhancement and addiction reduction?
Answer: False
No, potential long-term concerns include possible memory and cognition problems, and the risk of addiction, rather than memory enhancement or addiction reduction.
Is Cannabinoid Hyperemesis Syndrome (CHS) characterized by relief from nausea due to long-term cannabis use?
Answer: False
No, CHS is paradoxically characterized by recurrent nausea and vomiting, often occurring with long-term, heavy cannabis use.
Does the American College of Obstetricians and Gynecologists recommend cannabis use during pregnancy for nausea relief?
Answer: False
No, the ACOG recommends that cannabis should not be used during pregnancy or lactation due to potential risks to fetal development and infants.
Is cannabis use associated with an earlier onset of psychosis, especially in adolescents?
Answer: True
Yes, research indicates that cannabis use is linked to an earlier onset of psychosis, particularly in adolescents and genetically predisposed individuals.
Is cannabis use during pregnancy considered safe according to the American College of Obstetricians and Gynecologists?
Answer: False
No, the ACOG advises against cannabis use during pregnancy and lactation due to potential risks to fetal development and infants.
Which of the following is a commonly reported short-term adverse effect of medical cannabis?
Answer: Drowsiness and dizziness
Common short-term adverse effects of medical cannabis include dizziness and feeling tired, which may impair abilities such as driving until tolerance develops.
What potential long-term risk is associated with chronic medical cannabis use?
Answer: Potential memory and cognition problems, and risk of addiction
Potential long-term concerns include possible memory and cognition problems, the risk of addiction, and the potential to trigger schizophrenia in susceptible individuals, particularly adolescents.
Cannabinoid hyperemesis syndrome (CHS) is paradoxically associated with which symptom?
Answer: Recurrent nausea and vomiting
Cannabinoid Hyperemesis Syndrome (CHS) is paradoxically characterized by recurrent episodes of severe nausea and vomiting, often occurring with long-term, heavy cannabis use.
What complex relationship exists between cannabis use and mental health disorders, particularly psychosis?
Answer: Cannabis use is associated with an increased risk of psychosis, especially in predisposed individuals.
Evidence suggests that cannabis use, particularly high-THC varieties, is associated with an increased risk of psychosis, especially in adolescents and genetically predisposed individuals. It can trigger acute psychotic episodes and may contribute to the development of chronic psychotic disorders.
What recommendation do the American College of Obstetricians and Gynecologists make regarding cannabis use during pregnancy?
Answer: Cannabis should not be used during pregnancy or lactation.
The American College of Obstetricians and Gynecologists advises against cannabis use during pregnancy and lactation due to potential risks to fetal development and infant well-being.
What is a significant finding regarding cannabis use and the onset of psychosis?
Answer: It is associated with an earlier onset of psychosis, especially in adolescents.
Evidence suggests that cannabis use, particularly high-THC varieties, is associated with an increased risk of psychosis, especially in adolescents and genetically predisposed individuals. It can trigger acute psychotic episodes and may contribute to the development of chronic psychotic disorders.
What potential adverse mental health effect is strongly associated with cannabis use, particularly in certain individuals?
Answer: Increased risk of psychosis
Cannabis use is linked to an increased risk of psychosis, especially in adolescents and genetically predisposed individuals. It can trigger acute psychotic episodes and may contribute to the development of chronic psychotic disorders.
Has the U.S. FDA approved smoked cannabis for treating specific medical conditions?
Answer: False
No, the U.S. FDA has not approved smoked cannabis for any medical condition due to a lack of evidence concerning its safety and efficacy.
Is cannabis classified as a Schedule I drug under the UN Single Convention on Narcotic Drugs?
Answer: True
Yes, cannabis is classified as a Schedule I drug under the 1961 Single Convention on Narcotic Drugs, indicating medical indispensability but also risks of abuse.
Is medical cannabis legal at the federal level in the US but restricted in many states?
Answer: False
No, medical cannabis is illegal at the federal level in the US (Schedule I drug) but is legal in many states, with federal prosecution restricted by amendments like Rohrabacher-Farr.
Do health insurance companies in the US typically cover medical marijuana prescriptions due to its federal approval?
Answer: False
No, health insurance companies generally do not cover medical marijuana because it lacks federal FDA approval, which stems from its Schedule I classification.
Does the American Medical Association (AMA) strongly advocate for the legalization of medical cannabis?
Answer: False
No, the AMA does not strongly advocate for legalization but rather supports rescheduling cannabis to facilitate research into its safety and efficacy.
Are Dronabinol and Nabilone International Nonproprietary Names (INN) for specific cannabinoids?
Answer: True
Yes, Dronabinol (synthetic delta-9-THC) and Nabilone (a synthetic cannabinoid analog) are recognized International Nonproprietary Names (INN).
Is Nabiximols (Sativex) approved in the United States for treating MS spasticity?
Answer: False
No, Nabiximols (Sativex) is approved in several European countries and Canada for MS spasticity, but not yet in the United States.
Are Dronabinol and Nabilone classified as Schedule II substances by the FDA in the US?
Answer: True
Yes, Dronabinol (synthetic THC) and Nabilone are classified as Schedule II substances by the FDA, indicating a high potential for abuse and addiction.
Do the UN drug control treaties classify cannabis in a way that prohibits any medical use?
Answer: False
No, the UN drug control treaties classify cannabis as medically indispensable but require control over its abuse potential, allowing for regulated medical use.
Does the American Academy of Pediatrics support the legalization of medical cannabis?
Answer: False
No, the American Academy of Pediatrics opposes the legalization of medical cannabis, while also supporting rescheduling to facilitate research.
Do medical organizations advocate for rescheduling cannabis primarily to increase its recreational availability?
Answer: False
No, medical organizations advocate for rescheduling primarily to facilitate more extensive research into its safety and efficacy, not for recreational availability.
Have the WHO's recommendations influenced the international scheduling of cannabis under UN drug control treaties?
Answer: True
Yes, WHO recommendations have influenced UN treaty scheduling, such as the removal of cannabis from Schedule IV of the Single Convention on Narcotic Drugs in 2020.
Does the Rohrabacher-Farr amendment restrict federal prosecution related to state medical cannabis laws?
Answer: True
Yes, the Rohrabacher-Farr amendment limits the Department of Justice's ability to interfere with the implementation of state medical cannabis laws.
What is the U.S. FDA's official stance on smoked cannabis for medical use?
Answer: Not approved due to lack of safety and efficacy evidence.
The U.S. Food and Drug Administration (FDA) has not approved smoked cannabis for any medical condition due to insufficient evidence regarding its safety and efficacy. In 2006, the FDA stated marijuana has a high potential for abuse, no accepted medical use in the U.S., and lacks accepted safety for medical supervision.
Under which UN drug control treaty is cannabis classified as a Schedule I drug?
Answer: The Single Convention on Narcotic Drugs (1961)
Cannabis is classified as a Schedule I drug under the 1961 Single Convention on Narcotic Drugs, indicating medical indispensability but also risks of abuse and addiction.
Why do US health insurance companies generally not cover medical marijuana?
Answer: Because the FDA has not approved it as a medicine.
Health insurance companies in the US generally do not cover medical marijuana primarily because it lacks FDA approval. This lack of approval is largely due to cannabis's federal Schedule I classification, which has historically impeded comprehensive research.
Which major medical organization opposes the legalization of marijuana for medical use?
Answer: American Academy of Pediatrics
The American Academy of Pediatrics (AAP) reaffirms its opposition to the legalization of marijuana for medical use, citing potential risks, while also supporting rescheduling to facilitate research.
What are the International Nonproprietary Names (INN) mentioned for specific cannabinoids?
Answer: Dronabinol, Cannabidiol, Nabilone
The International Nonproprietary Names (INN) granted for specific cannabinoids include Dronabinol (for synthetic delta-9-THC), Cannabidiol (CBD), and Nabilone (a synthetic cannabinoid analog).
Nabiximols, known by the brand name Sativex, is approved for medical use in which region?
Answer: Several European countries, Canada, and New Zealand.
Nabiximols, marketed as Sativex, is an oromucosal spray containing a THC-CBD mixture. It is approved in several European countries, Canada, and New Zealand for conditions such as MS spasticity and cancer pain, but it is not yet approved in the United States.
What major factor has historically hindered research into medical cannabis?
Answer: Legal and governmental restrictions.
Studying medical cannabis is challenging due to significant legal and governmental restrictions that have historically limited research. The complexity of the plant, containing over 400 compounds including around 70 cannabinoids, also presents difficulties in isolating and studying specific effects.
What is the FDA classification for dronabinol (synthetic THC) in the United States?
Answer: Schedule II
In the United States, dronabinol (synthetic delta-9-THC) is classified as a Schedule II substance by the FDA, indicating a high potential for abuse and addiction.
What is the primary argument cited by medical organizations for rescheduling cannabis?
Answer: To facilitate more extensive research into its safety and efficacy.
Medical organizations advocate for rescheduling cannabis primarily to facilitate more extensive research into its safety and efficacy, enabling better regulatory oversight and safer patient access.
What is the significance of the UN drug control treaties concerning cannabis availability?
Answer: They classify cannabis as medically indispensable but require control over abuse potential.
The UN drug control treaties regulate cannabis, classifying it as medically indispensable but requiring control over its abuse potential, influencing international availability and member state obligations.
Is medical cannabis defined exclusively as isolated chemical compounds derived from the marijuana plant?
Answer: False
Medical cannabis is defined as the use of the whole plant or its extracts to treat symptoms or diseases, contrasting with conventional medications that typically use single or few isolated chemicals. Thus, it is not defined solely as isolated compounds.
Are landrace strains modern cannabis hybrids developed through selective breeding?
Answer: False
No, landrace strains are cultivars that developed naturally in specific geographic regions over centuries, distinct from modern hybrids created through selective breeding.
Is the term 'medical marijuana' distinct from 'medical cannabis' and refers only to recreational use for symptom management?
Answer: False
No, 'medical marijuana' and 'medical cannabis' are often used interchangeably and refer to the therapeutic use of cannabis for diseases or symptoms, not recreational use.
According to the National Institute on Drug Abuse (NIDA), what is the primary distinction between medical cannabis and conventional medications?
Answer: Medical cannabis involves the whole plant or its extracts, unlike conventional drugs which typically use single or few isolated chemicals.
NIDA defines medical cannabis as the use of the whole plant or its extracts to treat diseases or symptoms, contrasting with conventional medications that typically utilize single or few isolated chemicals.
What does the term 'landrace strain' refer to in cannabis cultivation?
Answer: A cultivar that developed naturally in a specific geographic region over centuries.
A 'landrace strain' refers to a cannabis cultivar that has developed naturally over centuries in a specific geographic region, adapting to local environmental conditions. These are distinct from modern hybrids created through selective breeding.